Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is the most common acute leukemia that is becoming more prevalent particularly in the older (65 years of age or older) population. For decades, “7 + 3” remission induction therapy with cytarabine and an anthracycline, followed by consolidation therapy, has been the stand...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Kent T. J., Gilabert-Oriol, Roger, Bally, Marcel B., Leung, Ada W. Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Expert Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591181/
https://www.ncbi.nlm.nih.gov/pubmed/31236772
http://dx.doi.org/10.1007/s11095-019-2654-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591181/
https://www.ncbi.nlm.nih.gov/pubmed/31236772
http://dx.doi.org/10.1007/s11095-019-2654-z

Ejemplares similares